

KNOW LABS

TRANSFORMING NON-INVASIVE MEDICAL DIAGNOSTICS

Annual Shareholder Meeting
FY2024

September 26, 2024



Agenda

1. Introductions
2. Vote Report
3. Business Update
4. Q&A

Disclaimers

Safe Harbor Statement

This document contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2020, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

Business Update

1. Capital Raise & Implications
2. Strategic Priorities and Operational Adjustments
3. FY2025 and Beyond

Capital Raise Update

Date	Event	KNW	Market Cap	Deal Size
June 10	-	\$0.86	\$71M	-
June 17	S-1	\$0.71	\$61M	\$15M
July 2	S-1A	\$0.40	\$33M	\$6.5M
July 9	S-1A	\$0.39	\$31M	\$6.0M
July 22	S-1A	\$0.41	\$34M	\$6.0M
July 25	S1-A	\$0.37	\$30M	\$4.0M
August 8	Pricing	\$0.28	\$23M	\$3.445M
August 12	Closing	\$0.29	\$23M	\$3.445M
August 16	2 nd Tranche	\$0.30	\$24M	\$1.655M
August 20	15% over-allotment	\$0.30	\$25M	\$0.5M

~\$46 million market value erased since the June 17th public filing

Offering terms revised 5 times

Gross Proceeds

- 1st tranche: \$3.445M
- 2nd tranche: \$1.655M
- 15% over-allotment: \$0.520M

Total: \$5.6M

Total gross proceeds were approximately **37% of the total expected to be raised (\$15M)**

Know Labs must re-align goals, activities, and organization to this **new reality.**

Short-selling → 65% market value reduction



Short-selling volume before public offering announcement (June 17, 2024)

Short-selling volume sharply increased during the 8-week financing (post 17, 2024)

Short Interest at a 5-year high resulting in a ~\$46M market cap reduction in less than 8 weeks (65%)

Know Labs

We continue focused on building the
Next Generation of Non-Invasive
Medical Diagnostics, starting with
Blood Glucose Monitoring.

Know Labs

Our patented and proprietary radio frequency glucose monitoring device is a game changer, but its development is not simple.

Know Labs

The development path is **complex** and **expensive** for a \$50M market cap company





- Lengthy and costly path to clearance (>\$75M)
- A long list of interferences to address:
 - Some have been addressed – eg integration with other mobile/wearable devices
 - Others are still in progress – eg deconvolve other analytes and non-analytes changes
- Potential need to integrate with other sensors to increase accuracy and generalizability
- Further miniaturization to increase adoption and market potential

We have built a strong R&D foundation capable of excelling on this path

Additional info will be provided in the next slides

- Robust research platform (Gen 0, 1 and 2)
- Form-factor agnostic
- Proven to work (peer-reviewed validation)
- Multi-analyte application (O2, glucose, alcohol, metabolized drugs, ketones, etc.)
- Insensitive to skin tone
- Interoperability & Integration
- RF expertise (on/off Bluetooth/Wi-Fi)
- Know Labs has followed the directions of other smaller companies
 - IP Leader → 300+ patent assets
 - Best in class trade secret process → 600+ trade secrets documented

Know Labs R&D Roadmap: 2019 to Today

2019: Proof-of-Concept	2021: Generation 0	2023: Generation 1	2024: Generation 2
			 <p>KnowU</p>
<ul style="list-style-type: none">• Exploratory design• Multiple components wired to each other• Signal testing purpose• 2 x 3 ft board	<ul style="list-style-type: none">• Miniaturized format• Wired connection to power source and data capture• Restricted to laboratory controlled environment	<ul style="list-style-type: none">• On-the-go form factor• Place your palm or arm for an on-demand, non-invasive blood glucose level• Computer mouse size	<ul style="list-style-type: none">• Wearable form factor• Continuous monitoring• 85% smaller and 75% lighter than previous Generation

Gen 1: Benchtop Research Form Factor



Gen 1

- Computer mouse size
- Research Lab in your pocket to accelerate data collection



Using Gen 1 Prototype on Forearm



Using Gen 1 Prototype on Hand

Gen 2: Wearable Research Form Factor




Worn with Strap



Worn with Adhesive

Mobile App




Validation: Stability, Repeatability and Accuracy

Peer-Reviewed Publications



September 1, 2024

July 8, 2024




DTT Journal
93.37% Accuracy

A Glycemic Status Classification Model Using a Radiofrequency Noninvasive Blood Glucose Monitor.

A study titled, "A Glycemic Status Classification Model Using a Radiofrequency Noninvasive Blood Glucose Monitor," demonstrates the accuracy of Know Labs' proprietary non-invasive radiofrequency (RF) dielectric sensor and trade-secret machine learning (ML) algorithms in classifying an individual's glycemic status as hyperglycemic, normoglycemic, or hypoglycemic with 93.37% accuracy compared to venous blood glucose values—serving as an early proof-of-concept for a novel, non-invasive diabetes screening device.

Peer-Reviewed By: [Diabetes Technology & Therapeutics Journal](#)

Karim F, Anderson JH, Currie K, Bui C, Klyve D, Sor Status Classification Model Using a Radiofrequency
doi:10.1089/dia.2024.0170



ADA/2024
11.8% MARD
Others: ATTD, APS, AACE

Clinical Research Study Among PWD Using a Venous Blood Comparator Demonstrates a Stable MARD in an Expanded Dataset.

June 21, 2024

A study titled, "A New Machine Learning Model and Expanded Dataset for a Non-Invasive BGM," assesses the accuracy of the novel Know Labs radiofrequency (RF) dielectric sensor for non-invasive blood glucose measurement in participants with prediabetes and Type 2 diabetes using venous blood as comparative reference. Results were presented as a poster at the [American Diabetes Association's 84th Scientific Sessions](#).


Reviewed By: Abstract Review Committee [American Diabetes Association's 84th Scientific Sessions](#).

Klyve D, Anderson JH, Currie K, Bui C, Karim F, Somers VK. Published March 6, 2024. Non-Invasive Blood Glucose Monitoring in People with Diabetes Using an RF Sensor and Venous Blood Comparator. The American Diabetes Association's 84th Scientific Sessions, Orlando, FL.

IP-Protected: Global IP Leadership

Know Labs Patent Portfolio

of Active Patent Assets
Issued / Pending / In-Process



March 2022 to March 2024: IP portfolio grew 7.4x

Strategic IP development program

- 332 patents = 63 granted, 264 pending and 5 in-process
- 109% YoY growth, 3.1x IP market growth of ~35%
- Global coverage with patent assets in the US, PCT and 16 other jurisdictions worldwide

“Can’t Go Alone”

**Strategic
collaborations
to bootstrap
time-to-market**

- Implementation of additional sensors
- Clinical data collection acceleration
- Continued work to mitigate interferences
- Further miniaturization – current format vs. ASIC
- Other applications – context vs. reading, medical vs. wellness, reduced operating range, etc.
- Integration with other devices
- Other analytes/biomarkers

Implementing adjustments that leverage the building blocks put in place in the last five years – enablers of partnerships with big players

Strategic Adjustments

Organization re-alignment to priorities

Technology functionality over regulatory compliance

Streamlined clinical testing

IP spending transition from invention-driven growth to NIGM IP leadership maintenance

FY2025 and Beyond

Focus on developing strategic collaborations and partnerships

Reduce burn rate over 30% by end of Q1 FY2025

Auxiliary revenue-generation opportunities

Short-term milestones to support incremental capital raise

Questions & Answers

THANK YOU!

